Ahead of World Triple Negative Breast Cancer Day, the Collectif Triplettes Roses is mobilizing for new treatments once morest triple negative breast cancer: a rare and aggressive type of cancer with a low survival rate.
A few days before World Triple Negative Breast Cancer Day on March 3, the Collectif Triplettes Roses is launching an appeal: it is asking for new treatments for people who suffer from it. The least common breast cancer, it represents regarding 15% of cases and affects regarding 9,000 people each year according to the High Authority for Health. Their median overall survival is 14.5 months, and the 5-year survival rate for this disease is only 11.3%. The Collective Triplettes Roses, born in December 2021 from the merger of Triplettes Roses and #MobilisationTriplettes, wishes make known the pathology and asks for “a project to set up a national platform for clinical trials for triplets” and “to act to obtain new innovative treatments in France as a matter of urgency”.
Read also >>> “We need to talk more regarding breast cancer in society so that women are less afraid of it”
Two new treatments authorized in 2021
The cause is progressing little by little since the association obtained in 2021 access to promising therapeutic protocols: Pembrolizumab, or Keytruda, an immunotherapy for patients in the first line of treatment, and Sacituzumab Govitecan (Trodelvy), an antibody combined with chemotherapy for patients who have already been subjected to two different therapies. Between 600 and 1000 people might benefit from this medicine from…
Read the rest of the article on Elle.fr
VIDEO – Health Book – Dr Christian Recchia: “Breast cancer in women is 12,000 deaths per year in France”
